Catalent, Inc. (NYSE:CTLT) Shares Acquired by Van ECK Associates Corp

Van ECK Associates Corp increased its holdings in Catalent, Inc. (NYSE:CTLT - Free Report) by 47.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 124,424 shares of the company's stock after acquiring an additional 39,983 shares during the quarter. Van ECK Associates Corp owned about 0.07% of Catalent worth $7,391,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Catalent during the second quarter valued at approximately $42,000. Longfellow Investment Management Co. LLC lifted its position in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock valued at $55,000 after purchasing an additional 305 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock valued at $58,000 after buying an additional 212 shares during the period. Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Catalent by 1,400.0% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,500 shares of the company's stock valued at $91,000 after purchasing an additional 1,400 shares during the period. Finally, Federated Hermes Inc. lifted its stake in shares of Catalent by 456.6% in the 2nd quarter. Federated Hermes Inc. now owns 2,833 shares of the company's stock worth $159,000 after purchasing an additional 2,324 shares during the period.

Analyst Upgrades and Downgrades

CTLT has been the subject of several analyst reports. Robert W. Baird reissued a "neutral" rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. Baird R W cut Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. William Blair reiterated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Royal Bank of Canada reiterated a "sector perform" rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. Finally, StockNews.com downgraded Catalent from a "hold" rating to a "sell" rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and eight have given a hold rating to the company. According to data from MarketBeat.com, Catalent presently has a consensus rating of "Hold" and a consensus target price of $59.83.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the business's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.31% of the company's stock.

Catalent Stock Down 0.5 %

NYSE CTLT traded down $0.30 on Friday, reaching $59.62. 623,682 shares of the stock traded hands, compared to its average volume of 2,043,079. Catalent, Inc. has a 12 month low of $32.38 and a 12 month high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The company has a fifty day moving average price of $60.01 and a 200-day moving average price of $58.05. The company has a market cap of $10.82 billion, a price-to-earnings ratio of -10.91, a PEG ratio of 2.06 and a beta of 1.16.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same quarter last year, the company earned ($0.10) earnings per share. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. As a group, research analysts forecast that Catalent, Inc. will post 0.95 EPS for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.